DiagnoCure’s Update Presentation during the Annual and Special Meeting of Shareholders
QUEBEC CITY, April 29, 2013 /PRNewswire/ – DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) reminds shareholders to attend its Annual and Special
Meeting of Shareholders to be held today, April 29(th), at 3pm EDT, at the offices of McCarthy Tetrault, 1000 de la
Gauchetiere Street West, Suite 2500, Montreal, Quebec, H3B 0A2.
At the completion of the formal business portion of the meeting, Dr.
Yves Fradet, President and Chief Medical Officer will make a
presentation during which he will touch upon the following topics:
-- An update on the Corporation's current status of the GCC and PCA3 products; -- A review of the Corporation's business model evolution; -- Initiation of a search for a full-time CEO to achieve maximum leverage from DiagnoCure's product development platform.
The presentation will be available on DiagnoCure’s website at www.diagnocure.com through a link on the Investors page; presentations, available from 3pm
for those unable to attend the meeting.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. Previstage(TM) GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development and
commercialization of a prostate cancer test using PCA3, DiagnoCure’s
proprietary molecular biomarker. Hologic Gen-Probe’s PROGENSA((R)) PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and the United States. For more
information, please visit www.diagnocure.com.
Forward looking statements
This release may contain forward looking statements that involve known
and unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as “anticipates”, “assumes”,
“believes”, “estimates”, “expects”, “intend”, “may”, “plans”,
“projects”, “should”, “will”, or the negative thereof or other
variations thereon. Forward-looking statements also include any other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the “safe-harbour”
provisions of applicable Canadian securities laws. By their very
nature, forward looking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure’s control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation’s
current objectives, strategic priorities, expectations and plans, and
in obtaining a better understanding of the Corporation’s business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forward looking statements.
For instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA((R)) PCA3, are based on management expectations and such outcome may vary
materially depending on global political and economic conditions,
dependence on collaboration partners, uncertainty of healthcare
reimbursement, and marketing and distribution challenges. In addition,
the reader is referred to the applicable general risks and
uncertainties described in DiagnoCure’s most recent Annual Information
Form under the heading “Risk Factors”. DiagnoCure undertakes no
obligation to publicly update or revise any forward looking statements
contained herein unless required by the applicable securities laws and
SOURCE DiagnoCure inc.